Trihexyphenidyl

Limits on what this shows

• Key negative/null findings: Przedborski 1995: trihexyphenidyl showed no significant Complex I inhibition in rat brain, unlike levodopa/dopamine.
• At-risk subgroups: None established in humans; all primary data is rodent or in-vitro.
• Counter-evidence on record: A 2008 Neuroscience Letters study found trihexyphenidyl pretreatment protective against hydrogen peroxide-induced oxidative damage in PC12 cells, the opposite direction from the peripheral-organ findings above; this is a tissue- and context-specific reverse signal, not a resolution of the mitochondrial-burden question either way.

Regulatory status

Not addressed in the DailyMed label; mitochondrial effects are not a labeled pharmacologic action of trihexyphenidyl.

Population evidence

Przedborski et al., Movement Disorders, 1995: rat brain homogenate study comparing several antiparkinsonian agents; trihexyphenidyl (along with molindone and clozapine) was "without significant effect" on mitochondrial Complex I activity, in contrast to levodopa and dopamine, which inhibited it dose-dependently. Separately, two 2025 rat organ-toxicity studies (lung, testis; 1.5 mg/kg/day oral trihexyphenidyl, 21 to 60 days, n=20 to 32 animals total) found elevated caspase-3 (apoptosis marker) alongside oxidative damage, reversed by co-administered coenzyme Q10.

Mechanism

Not established as a direct, named mitochondrial mechanism. The apoptosis signal in peripheral organs appears downstream of the oxidative stress entry below rather than a primary mitochondrial lesion; the brain Complex I data argue against a direct electron-transport-chain mechanism.

Counter-evidence held on record

All primary data are rodent or in-vitro, at doses and durations that do not map directly onto standard human oral Parkinsonism dosing. This is not evidence of human mitochondrial harm, and it is not a basis for recommending coenzyme Q10 or any other supplement; the cited studies used CoQ10 as a research probe in animals, not as a demonstrated human treatment.

Limits on what this shows

• Key negative/null findings: None of the three positive studies reported a measured parameter that moved in the opposite direction within the same tissue.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: A 2008 Neuroscience Letters PC12 cell study found trihexyphenidyl pretreatment attenuated, rather than worsened, hydrogen peroxide-induced oxidative damage in a neuronal-like cell line, a reverse-direction, tissue-specific finding. The gut-microbiome study above used a drug-dependence/withdrawal dosing model (escalating intraperitoneal dosing to 10 mg/kg/day) that is not equivalent to standard oral Parkinsonism dosing, which is an important active-dose limitation on generalizing its magnitude.

Regulatory status

Not addressed in the DailyMed label.

Population evidence

(1) Lung: BMC Pharmacology & Toxicology, 2025, 32 Wistar rats (4 groups of 8), oral trihexyphenidyl 1.5 mg/kg/day for 21 days (methods section states 9 weeks), found reduced catalase, glutathione peroxidase, superoxide dismutase, and reduced glutathione, with increased malondialdehyde, all reversed by co-administered coenzyme Q10 10 mg/kg/day. (2) Testis: Steroids, 2025, 20 Wistar rats (4 groups of 5), oral trihexyphenidyl 1.5 mg/kg/day for 60 days, found increased malondialdehyde and 8-hydroxy-2-deoxyguanosine with hormonal and steroidogenic disruption, reversed by the same coenzyme Q10 regimen. (3) Gut: Antioxidants, 2023 (Baslam et al.), Sprague Dawley rats in a dose-escalating dependence/withdrawal model (intraperitoneal trihexyphenidyl escalating from 5 to 10 mg/kg/day over 30 days, then 7-day withdrawal), found gut-tissue malondialdehyde roughly tripled (11.0 to 35.6 nmol/g) and superoxide dismutase and catalase activity reduced by more than half during withdrawal, alongside intestinal mucosal edema and inflammatory infiltration on histology.

Mechanism

Not established at the molecular level; consistent across three organ systems but not tied to a single named enzyme or receptor mechanism. Direction is consistently pro-oxidant in these three studies.

Counter-evidence held on record

This is a rodent-only, high-dose signal. It is not a basis for recommending antioxidant supplementation in people taking trihexyphenidyl; the coenzyme Q10 doses used in these animal studies do not translate to a human dose and no dose is recommended anywhere in this dossier.

Limits on what this shows

• Why no grade: Dual-condition test met: no Tier B or C evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white.

Channels tried

PubMed search-listing pages (query "trihexyphenidyl copper"; 10 results returned, all either an unrelated analytical-chemistry copper-nanocluster detection method or Wilson's disease case reports in which trihexyphenidyl is used to symptomatically treat the movement disorder caused by copper accumulation, a disease-intrinsic use excluded under Hard Rule 2, not a drug-caused copper effect). Crossref works API (query "trihexyphenidyl copper"; 5 results, all pharmaceutical reference/standard listings or an unrelated overdose case report, clean non-match). Europe PMC REST API: repeated HTTP 429 rate-limiting across this session for related queries, so this channel could not be genuinely searched for copper specifically. General web search for consumer nutrient-depletion claims naming trihexyphenidyl and copper: no relevant result surfaced before the session's search budget was exhausted; direct scraping of Bing and DuckDuckGo result pages was blocked by robots.txt or failed.

Limits on what this shows

• Why no grade: Dual-condition test met: no Tier B or C evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white.

Channels tried

PubMed search-listing pages (query "trihexyphenidyl iron"; 6 results, all case reports of brain-iron-accumulation disorders such as PKAN and Woodhouse-Sakati syndrome in which trihexyphenidyl treats the resulting dystonia symptomatically, a disease-intrinsic use excluded under Hard Rule 2, plus one unrelated colonoscopy-architecture paper reused under Gut microbiome risk). A dedicated PubMed query for "trihexyphenidyl AND hemoglobin" (relevant to iron-linked oxygen transport) returned a clean zero-result page with automatic term-mapping explicitly turned off, confirming no indexed literature rather than a search-syntax miss. Crossref works API query for iron/anemia terms returned an HTTP 429 during this session. Europe PMC REST API: repeated HTTP 429 across this session. General consumer-claim web search: no relevant result surfaced before the session's search budget was exhausted.

Limits on what this shows

• Key negative/null findings: No study located measured human gut microbiome composition directly in trihexyphenidyl users.
• At-risk subgroups: Patients already prone to severe constipation or megacolon (for example, the elderly, or those on additional anticholinergic or opioid medications) would plausibly carry more motility-driven microbiome risk, though this specific stratification has not been studied.
• Counter-evidence on record: The animal dysbiosis data come from a supraphysiologic, dose-escalating intraperitoneal dependence/withdrawal model, not standard oral therapeutic dosing, which limits how far the magnitude generalizes to ordinary Parkinsonism treatment. The human colonoscopy series is a retrospective, non-controlled case series rather than a prospective comparison against non-users.

Regulatory status

The DailyMed label documents dry mouth (30 to 50% of patients), constipation, and, in serious cases, paralytic ileus and colonic dilatation as labeled anticholinergic effects; it does not address microbiome composition.

Population evidence

Human: a retrospective colonoscopy series (Surgical Endoscopy, 2013;27(5):1601-1606) examined colonic architectural change in patients on psychotropic medications and specifically flagged trihexyphenidyl among drugs associated with megacolon and redundant-colon patterns (MeSH: "Megacolon, chemically induced"). This is a motility/architecture finding, not a direct microbiome measurement. Animal: Baslam et al., Antioxidants, 2023 (the same dependence/withdrawal study cited under Oxidative stress) found bacterial density fell from about 14.70x10^6 CFU/mL in controls to about 2.30x10^6 CFU/mL during trihexyphenidyl withdrawal (p<0.001), with qualitatively reduced taxonomic diversity (predominantly Firmicutes and Proteobacteria shifted in relative abundance) and intestinal mucosal inflammation on histology.

Mechanism

Named and plausible: antimuscarinic (M1/M3) blockade slows GI transit, a labeled, intended-class effect of trihexyphenidyl (not itself graded here, per Hard Rule 2); slowed transit plausibly alters the luminal environment enough to shift bacterial density and composition. This same motility mechanism is documented in benztropine's own label (another anticholinergic antiparkinsonian agent, ATC N04AC01, reviewed separately), so the motility-to-dysbiosis-risk mechanism is treated here as class-corroborated between these two specific, pharmacologically comparable agents, not extrapolated to the whole anticholinergic class.

Counter-evidence held on record

Megacolon and reduced GI motility are the drug's own known anticholinergic adverse effects, not a nutrient deficiency, and are not re-graded here; the gut-microbiome-risk flag is a distinct, downstream, lower-confidence inference from that motility effect. No probiotic or supplement dosing is recommended.

Limits on what this shows

• Key negative/null findings: Przedborski 1995 found no significant Complex I inhibition by trihexyphenidyl in rat brain, which is the step most directly upstream of ATP synthesis via oxidative phosphorylation.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: This is a single-organ (lung), single-study, rodent-only data set; no replication in a second organ or a second independent lab was found.

Regulatory status

Not addressed in the DailyMed label.

Population evidence

BMC Pharmacology & Toxicology, 2025 (the same lung-toxicity study cited under Oxidative stress): 32 Wistar rats, oral trihexyphenidyl 1.5 mg/kg/day for 21 days, found lactate dehydrogenase, pyruvate dehydrogenase, lactate, and pyruvate all elevated in lung tissue versus control, restored toward baseline by co-administered coenzyme Q10 10 mg/kg/day.

Mechanism

Not established as a primary ATP-synthesis lesion. Elevated lactate dehydrogenase and lactate alongside elevated pyruvate dehydrogenase and pyruvate is more consistent with a compensatory glycolytic and metabolic stress response to the oxidative damage described above than with a direct block of oxidative phosphorylation; the brain Complex I null finding (see Mitochondrial burden) argues against a direct electron-transport-chain lesion.

Counter-evidence held on record

Do not extrapolate a single rodent lung data set to systemic human energy metabolism, and do not read the coenzyme Q10 reversal in these animals as a basis for recommending CoQ10 or any other supplement in people taking trihexyphenidyl.

Limits on what this shows

• Why no grade: Dual-condition test met: no Tier B or C evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white.

Channels tried

PubMed direct query "trihexyphenidyl AND hemoglobin": clean zero result, automatic term-mapping off, confirming a genuine absence in the indexed literature rather than a blocked attempt. Crossref works API query "trihexyphenidyl oxygen hemoglobin": 5 results, all either synthetic hemoglobin-based oxygen-carrier product literature or an unrelated overdose case report, clean non-match. DailyMed label: reviewed in full for this dossier; contains no hematologic or oxygen-delivery language (see Pharmacokinetic basis). Europe PMC REST API: not separately queryable for this term this session due to persistent HTTP 429 responses. The drug's own documented tachycardia and impaired-sweating/anhidrosis effects (see Monitoring panel) are labeled anticholinergic pharmacology and thermoregulatory effects, not an oxygen-delivery mechanism, so they were not used to force a yellow grade here, per Hard Rule 2.